CervoMed Presents Interim Data Showing Biomarker Reduction With Neflamapimod
Twenty-four-week interim data showed an exposure-dependent reduction in neurofilament light chain, a biomarker of neuronal damage. Full biomarker and clinical data are expected in the first quarter.